Mapping How 100+ Cannabis Plant Compounds Interact with the Body

THC acts as a high-potency, low-efficacy agent at the CB1 receptor, while CBD has many lower-potency targets — but the pharmacology of most phytocannabinoids, especially acid forms, remains poorly studied.

Alexander, Stephen P H·Current topics in behavioral neurosciences·2026·Moderate EvidenceReview
RTHC-08071ReviewModerate Evidence2026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Over 100 unique cannabinoid metabolites exist in cannabis, but pharmacological understanding is heavily concentrated on THC (CB1 partial agonist) and CBD (multiple low-potency targets), with acid phytocannabinoids particularly understudied.

Key Numbers

Over 100 apparently unique cannabinoid metabolites identified in cannabis; THC is relatively high-potency but low-efficacy at CB1; CBD's molecular targets are lower potency with unclear human relevance.

How They Did This

Review of in vitro pharmacological data on plant-derived cannabinoids, assessing molecular targets, potency, and efficacy across the major and minor phytocannabinoid classes.

Why This Research Matters

Most cannabis science focuses on just two of 100+ compounds — understanding the full pharmacological landscape could unlock new therapeutic applications and explain the 'entourage effect.'

The Bigger Picture

The massive gap in our understanding of minor cannabinoids and acid forms (like THCA and CBDA) means we may be missing important therapeutic compounds hiding in plain sight in the cannabis plant.

What This Study Doesn't Tell Us

In vitro pharmacology often doesn't predict in vivo effects; many studies use non-physiological concentrations; acid cannabinoid data is particularly sparse.

Questions This Raises

  • ?Which acid phytocannabinoids have the most therapeutic potential?
  • ?Can the entourage effect be explained by specific minor cannabinoid-receptor interactions?

Trust & Context

Key Stat:
Evidence Grade:
Authoritative pharmacological review from a recognized cannabinoid researcher, grounded in in vitro data with acknowledged gaps in translation to human effects.
Study Age:
Published in 2026, providing a current assessment of the state of phytocannabinoid pharmacology research.
Original Title:
The Pharmacological Profile of Plant-Derived Cannabinoids In Vitro.
Published In:
Current topics in behavioral neurosciences, 76, 1-36 (2026)
Database ID:
RTHC-08071

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

How many active compounds are in cannabis?

Over 100 apparently unique cannabinoid metabolites have been identified, but the pharmacology of most is poorly understood. Research has heavily focused on just THC and CBD.

What's the difference between how THC and CBD work?

THC acts with relatively high potency but low efficacy at the CB1 receptor. CBD interacts with many different molecular targets but at lower potency, and the relevance of these interactions in humans remains unclear.

Read More on RethinkTHC

Cite This Study

RTHC-08071·https://rethinkthc.com/research/RTHC-08071

APA

Alexander, Stephen P H. (2026). The Pharmacological Profile of Plant-Derived Cannabinoids In Vitro.. Current topics in behavioral neurosciences, 76, 1-36. https://doi.org/10.1007/7854_2025_605

MLA

Alexander, Stephen P H. "The Pharmacological Profile of Plant-Derived Cannabinoids In Vitro.." Current topics in behavioral neurosciences, 2026. https://doi.org/10.1007/7854_2025_605

RethinkTHC

RethinkTHC Research Database. "The Pharmacological Profile of Plant-Derived Cannabinoids In..." RTHC-08071. Retrieved from https://rethinkthc.com/research/alexander-2026-the-pharmacological-profile-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.